In summary, these results suggest that licMABs interfere with the CD47-SIRPα axis upon tumor antigen binding, thus blocking the inhibitory signal in macrophages and enhancing specific phagocytosis of target AML cell lines. This evidence concerns the gene CD47 and acute myeloid leukemia.